CN103249428A - 钙调磷酸酶抑制因子1在制备治疗与NF-κB活性升高相关的疾病的药物中的用途 - Google Patents

钙调磷酸酶抑制因子1在制备治疗与NF-κB活性升高相关的疾病的药物中的用途 Download PDF

Info

Publication number
CN103249428A
CN103249428A CN2011800472596A CN201180047259A CN103249428A CN 103249428 A CN103249428 A CN 103249428A CN 2011800472596 A CN2011800472596 A CN 2011800472596A CN 201180047259 A CN201180047259 A CN 201180047259A CN 103249428 A CN103249428 A CN 103249428A
Authority
CN
China
Prior art keywords
amino acid
acid sequence
peptide
cancer
seqidno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2011800472596A
Other languages
English (en)
Other versions
CN103249428B (zh
Inventor
李文博
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Weizhen Biological Technology Co ltd
Original Assignee
Shandong Weizhen Biological Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Weizhen Biological Technology Co ltd filed Critical Shandong Weizhen Biological Technology Co ltd
Publication of CN103249428A publication Critical patent/CN103249428A/zh
Application granted granted Critical
Publication of CN103249428B publication Critical patent/CN103249428B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明提供了包含SEQ ID NO：3的氨基酸序列的肽、或其编码核酸在制备用于治疗与NF-кB活性升高相关的疾病的药物中的应用。该肽可与IKB相互作用，并影响IKB在42位酪氨酸的磷酸化，从而抑制NF-кB信号通路。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN201180047259.6A 2011-04-25 2011-04-25 钙调磷酸酶抑制因子1在制备治疗与NF-κB活性升高相关的疾病的药物中的用途 Active CN103249428B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2011/073261 WO2012145890A1 (zh) 2011-04-25 2011-04-25 钙调磷酸酶抑制因子1在制备治疗与NF-κΒ活性升高相关的疾病的药物中的用途

Publications (2)

Publication Number Publication Date
CN103249428A true CN103249428A (zh) 2013-08-14
CN103249428B CN103249428B (zh) 2014-03-12

Family

ID=47071545

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180047259.6A Active CN103249428B (zh) 2011-04-25 2011-04-25 钙调磷酸酶抑制因子1在制备治疗与NF-κB活性升高相关的疾病的药物中的用途

Country Status (5)

Country Link
US (1) US20140142045A1 (zh)
EP (1) EP2703006A4 (zh)
JP (1) JP5898304B2 (zh)
CN (1) CN103249428B (zh)
WO (1) WO2012145890A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108926713A (zh) * 2017-05-26 2018-12-04 上海市肿瘤研究所 钙调磷酸酶调节蛋白1.4或其类似物在制备抑制肝癌的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1504483A (zh) * 2002-11-29 2004-06-16 重庆医科大学 一种NF-κB抑制物及其制备方法、以及作为抗肿瘤药物的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200407160A (en) * 2002-10-08 2004-05-16 Kazuhito Tomizawa Inhibitors for continuous activation of calcineurin
JPWO2005082412A1 (ja) * 2004-02-26 2007-10-25 株式会社ペルセウスプロテオミクス 癌の治療および予防薬

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1504483A (zh) * 2002-11-29 2004-06-16 重庆医科大学 一种NF-κB抑制物及其制备方法、以及作为抗肿瘤药物的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DS BASSERES等: "Nuclear factor-kB and inhibitor of kB kinase pathways in oncogenic initiation and progression", 《ONCOGENE》 *
YONG JUN YANG等: "Rcan1 negatively regulates FceRI-mediatedsignaling and mast cell function", 《THE JOURNAL OF EXPERIMENTAL MEDICINE》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108926713A (zh) * 2017-05-26 2018-12-04 上海市肿瘤研究所 钙调磷酸酶调节蛋白1.4或其类似物在制备抑制肝癌的药物中的应用

Also Published As

Publication number Publication date
US20140142045A1 (en) 2014-05-22
CN103249428B (zh) 2014-03-12
WO2012145890A1 (zh) 2012-11-01
EP2703006A1 (en) 2014-03-05
EP2703006A4 (en) 2014-10-22
JP2014513086A (ja) 2014-05-29
JP5898304B2 (ja) 2016-04-06

Similar Documents

Publication Publication Date Title
Siegrist et al. The small interferon-induced transmembrane genes and proteins
Li et al. Receptor complex and signalling pathway of the two type II IFNs, IFN-γ and IFN-γrel in mandarin fish or the so-called Chinese perch Siniperca chuatsi
PT2352508E (pt) Péptidos do domínio citoplasmático muc1 como inibidores de cancro
Hu et al. Molecular cloning and characterization of interferon regulatory factor 9 (IRF9) in Japanese flounder, Paralichthys olivaceus
JP2023546133A (ja) 汎ＲＡＳ ｍＲＮＡがんワクチン
CN111197057B (zh) 调控免疫细胞迁移的组合物和方法
Senapin et al. Knocking down a Taura syndrome virus (TSV) binding protein Lamr is lethal for the whiteleg shrimp Penaeus vannamei
Marban et al. Interplay between the HTLV-2 Tax and APH-2 proteins in the regulation of the AP-1 pathway
Zhao et al. Noxa and Puma genes regulated by hTERT promoter can mitigate growth and induce apoptosis in hepatocellular carcinoma mouse model
CA2251818A1 (en) Mammalian genes involved in viral infection and tumor suppression
CN103249428A (zh) 钙调磷酸酶抑制因子1在制备治疗与NF-κB活性升高相关的疾病的药物中的用途
CN108752435B (zh) 乙酰化戊型肝炎病毒衣壳蛋白orf2及其用途
Li et al. Bid is involved in apoptosis induced by Chinese giant salamander iridovirus and contributes to the viral replication in an amphibian cell line
CN112920258B (zh) 一种cd44拮抗多肽及其衍生物与应用
CN108026181B (zh) 一种TRAIL双靶点突变蛋白MuR6S4TR、其制备方法及其应用
US20170283457A1 (en) Use of inhibitory peptides for the treatment of inflammatory diseases
Zhang et al. Upregulation of PRDM5 is associated with astrocyte proliferation and neuronal apoptosis caused by lipopolysaccharide
CN108795882B (zh) 调节戊型肝炎病毒组装和衣壳蛋白orf2稳定性的方法
KR20170056902A (ko) C형 간염 바이러스 감염 또는 감염과 관련된 질병의 예방 또는 치료용 약학 조성물
JP2021520845A (ja) マイクロペプチドとその使用
Wang et al. Molecular cloning and multifunctional characterization of GRIM-19 (gene associated with retinoid-interferon-induced mortality 19) homologue from turbot (Scophthalmus maximus)
JP7417274B2 (ja) Ｂ型肝炎ウイルス複製阻害剤及びそれを含むｂ型肝炎治療用医薬組成物
WO2022253340A1 (zh) 环状RNA Circ-ACE2翻译的多肽及其应用
Li et al. Molecular characterization and transcriptional conservation of N-myc-interactor, Nmi, by type I and type II IFNs in mandarin fish Siniperca chuatsi
WO2022237621A1 (zh) 诊断和治疗肿瘤的试剂及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant